News in brief

Asahi Glass consolidates bio-CDMO acquisitions under AGC Biologics brand

By Staff Reporter

- Last updated on GMT

Recent acquisitions CMC Biologics and Biomeva have been brought together under the single AGC Biologics brand in efforts to consolidate its CDMO business.

Over the past 18 months, Japanese glass solution provider AGC Asahi Glass has become a major biologics contract development and manufacturing organisation (CDMO) through the acquisitions of Biomeva GmbH​ and CMC Biologics​.

In total the firm offers 44,000L of microbial and mammalian biomanufacturing capacity through these acquisitions from six facilities in the US, Denmark, Germany and Japan.

As such, the firm has opted to consolidate the two acquisitions under a single brand, AGC Biologics, and has appointed former CMC Biologics head Gustavo Mahler as president and CEO of the combined entity.

“With our proven track record, I believe that we will clearly pave the way to a successful future, providing our clients solutions to their greatest development and manufacturing challenges, and enabling the delivery of breakthrough treatments to patients across the globe,”​ Mahler said.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more